Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for an audio roundup of major events in the international biopharma industry over the past week, as covered by Scrip's global team.

Take a brief audio tour round Scrip's Five Must-Know Things, this time for the business week ended 9 October 2020. 

In this edition, we look at the impact on clinical trials of President Trump’s treatment for COVID-19, a major acquisition by BMS, a planned EUA for Lilly’s covid antibody therapy, change at the top at Merck Research Labs, and a forward view on major new drug approvals expected in the coming months.

This and other Informa Pharma Intelligence podcasts are also now voice-accessible via Alexa smart speakers and the Alexa app, once set up as a skill. Just say “Alexa, Open Informa - Pharma Intelligence" and then ask for a specific podcast or topic.

Stories mentioned in this episode:

(Also see "Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire" - Scrip, 4 Oct, 2020.)

(Also see "BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten" - Scrip, 5 Oct, 2020.)

(Also see "Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data" - Scrip, 7 Oct, 2020.)

(Also see "Merck’s Perlmutter Is Retiring, Handing Over Keytruda To Li" - Scrip, 2 Oct, 2020.)

(Also see "12 Approvals To Look Out For In Q4" - Scrip, 7 Oct, 2020.)

 

Topics

UsernamePublicRestriction

Register

LL1134361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel